SCHEMBL4044041

SCHEMBL4044041

CCCC(NC(=O)c1ccc(OC)cc1)C(=O)N1CCC2C1C(=O)CN2S(=O)(=O)Cc1ccccn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 2/20 0.43
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 2/20 0.39
PKM P14618 1/20 0.38
SLC5A7 Q9GZV3 1/20 0.38
PREP P48147 1/20 0.37
FAP Q12884 1/20 0.37
KDM1A O60341 1/20 0.37
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
CCR1 P32246 2/20 0.36
P2RY12 Q9H244 1/20 0.36
GAA P10253 1/20 0.36
STS P08842 1/20 0.36
MMP1 P03956 1/20 0.36
MMP2 P08253 1/20 0.36
MMP3 P08254 1/20 0.36
MMP7 P09237 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4045232 0.94 CTSK (0.44) CTSKALDH1A1LMNAPKMSLC5A7
SCHEMBL4053232 0.93 CTSK (0.48) CTSKALDH1A1KMT2ALMNAPKM
SCHEMBL4040898 0.92 RAB9A (0.42) CTSKALDH1A1LMNAPKMSLC5A7
SCHEMBL4043681 0.92 CTSK (0.52) CTSKALDH1A1KMT2AMEN1LMNA
SCHEMBL4041378 0.92 CTSK (0.44) CTSKALDH1A1KMT2ALMNAPKM
SCHEMBL4039557 0.92 CTSK (0.42) CTSKALDH1A1KMT2AMEN1LMNA
SCHEMBL4039999 0.91 CTSK (0.54) CTSKALDH1A1KMT2AMEN1LMNA
SCHEMBL4040706 0.91 CTSK (0.45) CTSKALDH1A1LMNAPKMSLC5A7
SCHEMBL4042848 0.90 CTSK (0.54) CTSKALDH1A1KMT2AMEN1LMNA
SCHEMBL6235462 0.90 CCR1 (0.46) CTSKPREPFAPKDM1ACCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885ALDH1A1 4151/4885KMT2A 3867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.